Integration of New Biomarkers and Targeted Therapy in Advanced NSCLC: Challenges and Solutions
Release date 04-03-2021
Expiration date 04-03-2022
The treatment landscape for oncogene-driven advanced non-small cell lung cancer (NSCLC) is changing rapidly. The introduction of novel molecular targeted therapies against rare driver gene alterations that can be detected using techniques such as tissue- and plasma-based next-generation sequencing (NGS) has enhanced treatment options. However, integrating novel predictive biomarkers and targeted therapies in daily practice may be challenging.
Tetsuya Mitsudomi, MD, PhD | Chair
Kindai University Faculty of Medicine
Dr Tetsuya Mitsudomi is Professor at the Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka, Japan.
His research interests include surgical treatment of lung cancer and individualized treatment of lung cancer based on cancer genotypes such as EGFR mutations or ALK translocations. His group is also involved in studies of ctDNA and patient-derived organoids. He has published more than 400 papers that have featured in international peer-reviewed journals.
Dr Mitsudomi is President of the International Association for the Study of Lung Cancer (IASLC) (2019–2021) and is an active member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO). He also served as President of the Japanese Lung Cancer Society (2014–2018), and Board of Director of the Japanese Association of Chest Surgery (2013–2019) and the Japanese Society of Medical Oncology (2013–2019). He is also a council member of the Japanese Surgical Society, Japanese Cancer Association, Japanese Association of Thoracic Surgery, Japanese Society of Clinical Oncology, and Japan Respiratory Society, among others.
Dr Mitsudomi is an Associate Editor of Annals of Oncology (2014–2019), Journal of Thoracic Oncology (2017–present), Cancer Science (2007–present), Surgery Today, and Lung Cancer (2008–2013).
He is a recipient of Shinoi-Kawai Award from the Japan Lung Cancer Society (2001), JCA–Mauvernay Award from the Japanese Cancer Association (2005), Mary Matthews Award from the IASLC (2013), and Kiyoko and Paul Bourdarie-Goto Scientific Prize (2014).
Nick Pavlakis, MD, PhD
Royal North Shore Hospital
The University of Sydney
Dr Nick Pavlakis is a Senior Medical Oncologist at the Royal North Shore Hospital, North Shore Private Hospital, and Northern Cancer Institute (GenesisCare) in Sydney, Australia, and Associate Professor of Medicine at the Northern Clinical School, University of Sydney. He is also Co-Chair of the Bill Walsh Translational Cancer Research Laboratory at the Royal North Shore Hospital. He has more than 20 years’ experience in the oncology field, including clinical and translational research.
Dr Pavlakis trained in anti-angiogenic drug development and has an interest in new drug development and the evaluation of drug resistance in lung cancer, mesothelioma, and gastrointestinal malignancies. He is a Study Lead of several national and international co-operative group studies. He is a Deputy Chair of the IASLC CME Committee and has served on the Faculty of the World Conference on Lung Cancer (WCLC). He is the Board Chair of the new Thoracic Oncology Group of Australasia.
Keunchil Park, MD, PhD
Samsung Medical Center
Sungkyunkwan University School of Medicine
Keunchil Park is Professor of the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Professor Park has served as Chair of the Scientific Committee of the Korean Cancer Association (KCA), Chair of the Lung Cancer Committee of the Korean Cancer Study Group (KCSG), and also Chairman of the Board of Directors of the Korean Association for Clinical Oncology (KACO).
He is an active member of the International Association for the Study of Lung Cancer (IASLC) and has been involved in many IASLC activities since 1996, including Scientific Secretary of the 12th World Conference on Lung Cancer (WCLC; Sept, 2007), and President of the 4th Asia Pacific Lung Cancer Conference (Dec, 2010). He also served on the IASLC Board of Directors during 2009–2013. More recently, Professor Park served as Co-President (with Professor Hisao Asamura) of the 18th WCLC, Oct 15–18, 2017, Yokohama, Japan. He also received the Merit Award of IASLC in 2016.
Professor Park is also actively involved in a variety of international activities of ASCO (American Society of Clinical Oncology) as a member of the International Education Steering Group (IESG), and he leads the ASCO Asia Pacific Regional Council, being elected as Chair in 2019. He also served as Chair of the Korea Actionable Genome Consortium (KAGC) in 2015–2018 and the Scientific Co-Chair for ESMO-Asia 2017 (Nov 16–19, 2017, Singapore).
Professor Park is a member of the International Cancer Genome Consortium (ICGC) Scientific Steering Committee since 2013 and served as Organizing Chairman of the 13th ICGC workshop, June 12–14, 2017, in Seoul, Korea. He was nominated as Steering Committee member of ICGC Accelerating Research in Genomic Oncology (ICGC-ARGO), which is the second phase of ICGC and launched in May, 2018, and was recently appointed as Member of the Management Committee.
He is an Associate Editor for the Journal of Thoracic Oncology (JTO) and Therapeutic Advances in Medical Oncology, and an Editorial Advisory Board member of Cancer.
His main interests include translational research, as well as early clinical trials for lung cancer. Professor Park has led several early clinical trials of the targeted agents and immune check point inhibitors and pioneered developing precision oncology for lung cancer. He has also conducted many pre-clinical development programs as well as genomic research. Professor Park has written several book chapters and authored more than 400 peer-reviewed publications in national and international journals.
Daniel S.W. Tan, MD, PhD
National Cancer Centre Singapore
Genome Institute of Singapore
Dr Daniel Tan is a Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS), an Associate Professor at Duke-National Medical School, and a Senior Clinical-Scientist at the Genome Institute of Singapore. He is also Deputy Head of the Division of Clinical Trials and Epidemiological Sciences, and Director of the Experimental Cancer Therapeutics Unit (Phase I Unit) at NCCS. Dr Tan’s research interests are in thoracic and head and neck oncology, and cancer drug development. His work is focused on improving the understanding of determinants of response and resistance to targeted therapy and immunotherapy. He has published more than 100 peer-reviewed articles, many in high impact-factor journals. He has been the recipient of several national and international awards for his research, including the ASCO Merit Award twice, and in 2019, the IASLC Daniel C. Idhe Lectureship Award for Medical Oncology. Dr Tan serves as Associate Editor for the J Thoracic Oncol and is the conference co-chair for the World Conference in Lung Cancer (WCLC) in 2020, and the track chair for translational research at ESMO 2021.
- Optimizing biomarker testing in advanced NSCLC | Tetsuya Mitsudomi, MD, PhD
- When should we consider use of liquid biopsy in advanced NSCLC? | Nick Pavlakis, MD, PhD
- Incorporating targeted therapies for rare NSCLC molecular subtypes in patient care | Keunchil Park, MD, PhD
This educational activity is designed specifically for medical oncologists, pulmonologists, pathologists, and other clinicians involved in the management of patients with advanced NSCLC.
Upon completion of this educational activity, participants should be able to:
- Identify biomarkers that should be determined to provide optimal personalized treatment for patients diagnosed with advanced NSCLC, and recognize the importance of NGS profiling for the detection of rare mutations
- Assess how and when to use liquid biopsy in advanced NSCLC to detect actionable genomic alterations and mechanisms of resistance
- Evaluate efficacy and safety of new targeted therapies for uncommon molecular alterations, including MET-exon 14 skipping mutations, and determine appropriate use of new targeted therapies in clinical practice
Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This activity includes content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve knowledge, competence and performance of clinicians in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Tetsuya Mitsudomi has disclosed that he has served as an advisor or consultant for Astrazeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Eli-Lilly, Daiichi-Sankyo, Ono, ThermoFisher, BMS, MSD, Guardant, Novartis, Jansen, Eisai, and Amgen. He has served as a speaker or a member of a speakers bureau for AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Eli-Lilly, Ono, ThermoFisher, BMS, MSD, Guardant, and Novartis. Dr Mitsudomi has received grants for clinical research from Boehringer-Ingelheim, Chugai, AstraZeneca, Pfizer, Taiho, MSD, Sanofi-Aventis, and Kyowa-Hakko Kirin. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Keunchil Park has disclosed that he has served as an advisor or consultant for AMGEN, Astra Zeneca, BluePrint, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, JNJ, Merck KGaA, MSD, Puma Biotechnology, and Takeda. He has received grants for clinical research from Astra Zeneca, and MSD. Prof Park has other financial relationships with DSMB, BeiGene, and Incyte. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
Nick Pavlakis has disclosed that he has served as an advisor or consultant for Pfizer, Takeda, Boehringer Ingelheim, Amgen, Merck, Roche, MSD, BMS, and Novartis. He has received grants for clinical research from Bayer, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Daniel SW Tan has disclosed that he has served as an advisor or consultant for Novartis, Bayer, Boehringer Ingelheim, Celgene, Astra Zeneca, Eli-Lilly, and Loxo. He has received grants for clinical research from Novartis, Astra Zeneca, Pfizer, and Bayer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.